[go: up one dir, main page]

WO2004020599A3 - Antagonistes de la voie hedgehog, methodes et applications correspondantes - Google Patents

Antagonistes de la voie hedgehog, methodes et applications correspondantes Download PDF

Info

Publication number
WO2004020599A3
WO2004020599A3 PCT/US2003/027279 US0327279W WO2004020599A3 WO 2004020599 A3 WO2004020599 A3 WO 2004020599A3 US 0327279 W US0327279 W US 0327279W WO 2004020599 A3 WO2004020599 A3 WO 2004020599A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hedgehog antagonists
uses related
hedgehog pathway
inhibiting
Prior art date
Application number
PCT/US2003/027279
Other languages
English (en)
Other versions
WO2004020599A2 (fr
Inventor
Henryk K Dudek
Irina Karavanov
Carmen Pepicelli
Lee Rubin
Karen Kotkow
Original Assignee
Curis Inc
Henryk K Dudek
Irina Karavanov
Carmen Pepicelli
Lee Rubin
Karen Kotkow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Henryk K Dudek, Irina Karavanov, Carmen Pepicelli, Lee Rubin, Karen Kotkow filed Critical Curis Inc
Priority to AU2003265853A priority Critical patent/AU2003265853A1/en
Publication of WO2004020599A2 publication Critical patent/WO2004020599A2/fr
Publication of WO2004020599A3 publication Critical patent/WO2004020599A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des méthodes destinées à l'inhibition de l'angiogenèse et au traitement ou à la prévention de la prolifération cellulaire anormale, y compris des tumeurs, ces méthodes consistant à inhiber la voie hedgehog, à l'aide d'un des antagonistes de la voie hedgehog décrit dans la partie descriptive de la présente demande, par exemple.
PCT/US2003/027279 2002-08-29 2003-08-29 Antagonistes de la voie hedgehog, methodes et applications correspondantes WO2004020599A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265853A AU2003265853A1 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40714502P 2002-08-29 2002-08-29
US60/407,145 2002-08-29

Publications (2)

Publication Number Publication Date
WO2004020599A2 WO2004020599A2 (fr) 2004-03-11
WO2004020599A3 true WO2004020599A3 (fr) 2006-12-28

Family

ID=31978427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027279 WO2004020599A2 (fr) 2002-08-29 2003-08-29 Antagonistes de la voie hedgehog, methodes et applications correspondantes

Country Status (2)

Country Link
AU (1) AU2003265853A1 (fr)
WO (1) WO2004020599A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9708247B2 (en) 2013-03-15 2017-07-18 The Regents Of The University Of California Modulators of the eIF2alpha pathway

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CA2475879A1 (fr) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis de quinazolinones
NZ537076A (en) 2002-05-09 2007-06-29 Cytokinetics Inc Pyrimidinone compounds, compositions and methods
WO2003097053A1 (fr) 2002-05-09 2003-11-27 Cytokinetics, Inc. Composes, compositions et procedes
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (fr) 2002-07-23 2004-01-29 Cytokinetics, Inc. Composes, compositions et procedes
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005061460A1 (fr) 2003-12-08 2005-07-07 Cytokinetics, Inc. Composes, compositions, et methodes associees
AU2005231692B2 (en) * 2004-03-26 2011-01-27 Curis, Inc. RNA interference modulators of Hedgehog signaling and uses thereof
JPWO2006101273A1 (ja) * 2005-03-25 2008-09-04 武田薬品工業株式会社 癌の予防・治療剤
EP1966130B1 (fr) 2005-12-23 2013-12-11 Zealand Pharma A/S Composés modifiés mimétiques de la lysine
WO2008079266A2 (fr) 2006-12-21 2008-07-03 Wyeth Synthèse de composés de pyrrolidine
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2224807B1 (fr) 2007-12-27 2016-11-09 Infinity Pharmaceuticals, Inc. Procédés de réduction stéréosélective
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ587719A (en) 2008-02-26 2012-04-27 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US8404687B2 (en) 2008-11-03 2013-03-26 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
EA018372B1 (ru) 2008-11-17 2013-07-30 Эли Лилли Энд Компани Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
AU2009314349B2 (en) 2008-11-17 2013-04-18 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
JP5722781B2 (ja) 2009-08-26 2015-05-27 武田薬品工業株式会社 縮合複素環誘導体およびその用途
KR20120078703A (ko) 2009-08-26 2012-07-10 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 고리 유도체 및 이의 용도
EP2471793B1 (fr) 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Dérivé à noyaux hétérocycliques fusionnés et son utilisation
US8486965B2 (en) 2009-08-26 2013-07-16 Takeda Pharmaceutical Company Limited Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer
CA2799579A1 (fr) 2010-05-21 2011-11-24 Intellikine, Inc. Composes chimiques, compositions et procedes pour modulation de kinases
WO2012037217A1 (fr) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Hydrogénation par transfert d'analogues de cyclopamine
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
CA2842190A1 (fr) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Composes heterocycliques et leurs utilisations
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
CA2846431A1 (fr) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Composes heterocycliques et leurs utilisations
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX375194B (es) 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
WO2014151386A1 (fr) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CA2914284A1 (fr) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Traitement anticancer au moyen de modulateurs isoformes de la kinase p13
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104906113A (zh) * 2014-03-12 2015-09-16 淄博赛维医药技术有限公司 一种抗肿瘤药物
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (fr) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017139497A1 (fr) 2016-02-11 2017-08-17 PellePharm, Inc. Inhibiteur de la voie hedgehog destiné à être utilisé pour soulager et traiter le prurit ou les démangeaisons
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
CN110709096B (zh) 2017-05-05 2023-10-31 泽兰德制药公司 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
CA3198661A1 (fr) 2020-10-13 2022-04-21 Endeavor Biomedicines, Inc. Methodes de traitement de la fibrose

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FUJITA E. ET AL.: "Involvement of Sonic Hedgehog in the Cell Growth of LK-2 cells, Human Lung Squamous Carcinoma Cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH, vol. 238, 1997, pages 658 - 664, XP003005586 *
MCGARVEY T.W. ET AL.: "PTCH gene mutations in invasive transitional cell carcinoma of the bladder", ONCOGENE, vol. 17, 1998, pages 1167 - 1172, XP003005585 *
TAIPALE J. ET AL.: "Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine", NATURE, vol. 406, 31 August 2000 (2000-08-31), pages 1005 - 1009, XP002166408 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9708247B2 (en) 2013-03-15 2017-07-18 The Regents Of The University Of California Modulators of the eIF2alpha pathway
US10343981B2 (en) 2013-03-15 2019-07-09 The Regents Of The University Of California Modulators of the eIF2alpha pathway
US11220477B2 (en) 2013-03-15 2022-01-11 The Regents Of The University Of California Modulators of the eIF2alpha pathway

Also Published As

Publication number Publication date
AU2003265853A1 (en) 2004-03-19
AU2003265853A8 (en) 2004-03-19
WO2004020599A2 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004020599A3 (fr) Antagonistes de la voie hedgehog, methodes et applications correspondantes
WO2002030462A3 (fr) Antagonistes hedgehog, procedes et utilisations associees
WO2002032874A3 (fr) Composes heterocycliques substitues pour le traitement de resistance a des medicaments multiples
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2005030791A3 (fr) Inhibiteurs du canal potassique d'isoquinolinone
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2005030129A3 (fr) Inhibiteurs des canaux potassiques a la quinoleine
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2002046171A3 (fr) Derives d'anilinopyrimidine utilises comme inhibiteurs de kinase i$g(k)b (ikk), compositions et techniques associees
WO2004098494A3 (fr) Composés, compositions et procédés
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
WO2004022537A3 (fr) Composes heterocycliques
WO2002096361A3 (fr) Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase
WO2009006389A8 (fr) Composés utiles en tant qu'inhibiteurs de la kinase raf
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2001071022A3 (fr) Agonistes et antagonistes du recepteur lpa et procedes d'utilisation de ces derniers
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
WO2004032852A3 (fr) Procedes permettant de traiter l'arythmie cardiaque et de prevenir la mort due a l'arythmie cardiaque au moyen d'antagonistes du ngf
WO2006128143A3 (fr) Composes a base d'hydantoine
WO2005030130A3 (fr) Inhibiteurs des canaux potassiques a l'isoquinoleine
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2005016883A3 (fr) Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
WO2006034113A3 (fr) Analogues de quinolone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP